"Harvard Group's largest affiliate, Massachusetts General Hospital, has announced groundbreaking results of CAR-T therapy in combating the most malignant brain cancer—glioblastoma.
Immunotherapy is a method that uses a patient's own immune system to attack cancer cells. CAR-T therapy involves modifying the patient’s T cells—key immune cells—equipping them with what could be likened to mechanical arms, transforming them into 'biological weapons' capable of destroying cancer cells.
These mechanical arms are known as CARs (Chimeric Antigen Receptors), enabling them to precisely locate and kill cancer cells.
Traditionally used in blood diseases, CAR-T therapy has been successfully applied to glioblastoma at Massachusetts General Hospital, offering new hope to patients and paving new pathways for global cancer treatment.
CAR-T therapy is becoming a potent biological weapon, potentially marking the first major advancement in glioblastoma treatment since 1999."